Gt Biopharma, Inc.
Business: Pharma & Medical Devices | Pharmaceutical Companies
Recent News About Gt Biopharma, Inc. View More
-
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
-
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activites
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, issued an open letter from the CEO to shareholders, detailing the Company’s recent activities.
-
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced at Premium to Market
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 6,500,000 shares of the Company’s common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 6,500,000 shares of common stock at a combined purchase price of $1.00 per share of common stock (or common stock equivalent) and associated warrant in a registered direct offering.
-
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML 2022 at Upcoming ASH Annual Meeting
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML 2022 at Upcoming ASH Annual Meeting
-
GT Biopharma to Present New Data on Novel Dual -ntigen Teargeting Approach Against AML at Upcoming Ash Annual Meeting
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced the presentation of new data at the American Society of Hematology's 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13, 2022.
-
GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022.
-
GT Biopharma Announces Adjournment of Special Shareholders Meeting
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced that its 2022 Special Shareholders Meeting has been adjourned to October 10, 2022 at 11 a.m. PST due to lack of quorum for its previously scheduled meeting.
-
GT Biopharma Poster Presentation and Mini Oral Session at Esmo Congress 2022 Demonstrates GTB-5550 Trike Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced highlights of an accepted abstract titled, “B7H3-Targeted Tri-specific Killer Engagers deliver IL-15 to NK cells but not T cells, and specifically targets solid tumors as a pan-tumor antigen strategy mediated through NK cells,” for poster presentation both virtually at the European Society for Medical Oncology ("ESMO") Congress 2022 being held at the Paris Expo Porte de Versailles from September 9-13, in Paris, France.
-
GT Biopharma to Participate in the H.C Wainwright 24th Annual Global Investment Conference in September
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that management will present in-person at H.C. Wainwright’s 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace.
-
GT Biopharma Affirms Manufacturing Time For Lead Investigational Asset GTB-3650
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced entering into a Settlement and Investment Agreement (the “Agreement”) with its contract manufacturing partner Cytovance Biologics. The signed Agreement, covers all work required to facilitate the registration of an investigational new drug (IND) filing with the U.S. Food and Drug Administration (“FDA”) of its lead investigational asset GTB-3650.
-
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced second quarter fiscal 2022 results for the period ended June 30, 2022.
-
GT BIOPHARMA, INC: GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri Specific Killer Engager (Trike) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
GT Biopharma, Inc. (“the Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today, preclinical data in chronic lymphocytic leukemia (“CLL”) to be presented at the European Hematology Association (EHA) 2022 Congress.
-
GT BIOPHARMA INC: GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update
GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter fiscal 2022 results for the period ended March 31, 2022.
-
.jpg)
GT BIOPHARMA INC: GT Biopharma to Participate at H.C Wainwright Hybrid Global Investment Conference
GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced that management will present at H.C. Wainwright’s Hybrid Global Investment Conference
-
GT BIOPHARMA INC: GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 Trike Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022
GT Biopharma, Inc. (“the Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that it is presenting pre-clinical data at the American Association For Cancer Research Annual Meeting 2022.
-
GT BIOPHARMA, INC.:GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2021 results for the period ended December 31, 2021.
-
GT BIOPHARMA, INC.:GT Biopharma Presents Trike Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-Of-Concept Data At 2022 EBMT Annual Meeting
GT Biopharma, Inc. ("the Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today, preclinical data to be presented at the hybrid 48th European Society for Blood and Marrow Transplantation Annual Meeting (EBMT)
-
GT BIOPHARMA, INC.: GT Biopharma to Participate In-Person at 34th Annual Roth Conference, March 13-15, 2022
GT Biopharma to Participate In-Person at 34th Annual Roth Conference, March 13-15, 2022
-
GT BIOPHARMA, INC.: GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that GT Biopharma will be participating in the following upcoming medical conferences:
-
GT BIOPHARMA, INC.: GT Biopharma Appoints Manu Ohri As Chief Financial Officer
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced the appointment of Manu Ohri, who joins the Company as its Chief Financial Officer (CFO) effective immediately.